← Back to Search

Integrin antagonist

Lifitegrast 5% Ophthalmic Solution for Dry Eye Syndrome

Phase 4
Waitlist Available
Led By Danielle Iacono, OD
Research Sponsored by State University of New York College of Optometry
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks, 4 weeks, 8 weeks
Awards & highlights

Study Summary

This trial will compare the effects of a new eye drop medication to a control medication in people who wear contact lenses and have dry eye symptoms.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks, 4 weeks, 8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks, 4 weeks, 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in contact lens wearers
Secondary outcome measures
Change in tear osmolarity
Change in total score on the CLDEQ- 8 at 2 weeks and 4 weeks
Forced choice questionnaire
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Lifitegrast Ophthalmic Solution 5%Experimental Treatment1 Intervention
Group II: Lifitegrast Ophthalmic Solution VehiclePlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lifitegrast 5% Ophthalmic Solution
2021
Completed Phase 4
~490

Find a Location

Who is running the clinical trial?

State University of New York College of OptometryLead Sponsor
19 Previous Clinical Trials
1,104 Total Patients Enrolled
Novartis PharmaceuticalsIndustry Sponsor
2,855 Previous Clinical Trials
4,197,318 Total Patients Enrolled
Danielle Iacono, ODPrincipal InvestigatorState University of New York College of Optometry
1 Previous Clinical Trials
23 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants can partake in this clinical trial?

"Affirmative. Clinicaltrials.gov details that the research is actively seeking enrolment, having initially been posted on September 22nd 2022 and subsequently modified on September 23rd of the same year. The trial has a quota of 40 subjects spread across one medical centre."

Answered by AI

Are there any opportunities to join this clinical experiment at the present time?

"Affirmative. According to clinicaltrials.gov, this medical trial was originally posted on September 22nd 2022 and is presently looking for patients. Altogether, 40 people can join the study at a single site."

Answered by AI

What potential risks might patients incur when using Lifitegrast 5% Ophthalmic Solution?

"There is a wealth of evidence to suggest Lifitegrast 5% Ophthalmic Solution's safety, thus it was given an assessment score of 3."

Answered by AI

Who else is applying?

What state do they live in?
California
North Carolina
Texas
Other
How old are they?
65+
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
What site did they apply to?
State University of New York College of Optometry Clinical Vision Research Center
Recent research and studies
clinicaltrials.govStudy
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
Danielle Iacono 2022. "Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05505292.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top